Shopping Cart
- Remove All
Your shopping cart is currently empty
AM103
🥰Excellent
Catalog No. T10314Cas No. 1147872-22-7
Alias AM 103
AM103 is an effective and selective inhibitor of FLAP (IC50 = 4.2 nM).
AM103
🥰Excellent
Purity: 99.21%
Catalog No. T10314Alias AM 103Cas No. 1147872-22-7
AM103 is an effective and selective inhibitor of FLAP (IC50 = 4.2 nM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | 138 € | In Stock | |
| 5 mg | 344 € | In Stock | |
| 10 mg | 518 € | In Stock | |
| 25 mg | 933 € | In Stock | |
| 50 mg | 1.301 € | In Stock | |
| 100 mg | 1.786 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "AM103"
Diflapolin
T8844724453-98-9
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP) and soluble epoxide hydrolase (sEH) inhibitor, exhibiting marked anti-inflammatory efficacy and high target selectivity.
- 38 €
Size
QTY
MK-886
Cited
MK886, L 663536
T6893118414-82-7
MK-886 (L 663536) is an inhibitor of leukotriene biosynthesis, acting by inhibiting the 5-lipoxygenase-activating protein (FLAP), and serves as a moderately potent PPARα antagonist.
- 28 €
Size
QTY
CitedAtuliflapon
AZD5718
T90232041075-86-7
Atuliflapon (AZD5718) is a novel 5-Lipoxygenase Activating Protein(FLAP) inhibitor for Treatment of Coronary Artery Disease.
- 41 €
Size
QTY
Quiflapon
MK-591
T16087136668-42-3
Quiflapon (MK-591) causes cell apoptosis. Quiflapon is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor (IC50: 1.6 nM in a FLAP binding assay) and is also an effective and orally active Leukotriene biosynthesis (LT) inhibitor (IC50: 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively).
- 29 €
Size
QTY
Fiboflapon
GSK2190915, AM-803
T11487936350-00-4
Fiboflapon (GSK2190915) is an orally available and effective 5-lipoxygenase-activating protein (FLAP) inhibitor that binds FLAP with a titer of 2.9 nM and inhibition of LTB4 in human blood with an IC50 of 76 nM.
- 48 €
Size
QTY
LTB4-IN-2
T79389
LTB4-IN-2 (Compound 6x) is a selective inhibitor of Leukotriene B4 (LTB4), acting by specifically targeting the 5-Lipoxygenase-activating protein (FLAP) with an inhibitory concentration (IC 50) of 1.15 μM, thus serving as a potential agent for anti-inflammatory research [1].
- Inquiry Price
Size
QTY
sEH/FLAP-IN-1
T81181
sEH/FLAP-IN-1 (Compound 46A) serves as a dual inhibitor targeting both sEH and FLAP, effectively suppressing 5-LOX product formation with an EC50 of 11 nM in SACM-stimulated PBMCs, inhibiting sEH activity (EC50: 18 nM), and reducing thromboxane production. This compound is utilized in the study of inflammatory diseases [1].
- Inquiry Price
Size
QTY
FEN1-IN-7
T79135824983-90-6
FEN1-IN-7 (compound 16), a selective Flap endonuclease-1 (FEN1) inhibitor with an IC50 of 18 nM, plays a role in DNA damage repair in mammalian cells. Additionally, it targets the related endonuclease, xeroderma pigmentosum G (XPG), with an IC50 of 3.04 μM. FEN1-IN-7 enhances the sensitivity of cancer cells to potent DNA alkylating or methylating agents [1].
- Inquiry Price
Size
QTY
FEN1-IN-6
T79134824983-84-8
FEN1-IN-6 (compound 9) is a potent Flap endonuclease-1 (FEN1, IC50 = 10 nM) inhibitor, crucial for DNA damage repair in mammalian cells, and also targets the related endonuclease xeroderma pigmentosum G (XPG) with an IC50 of 23 nM [1].
- Inquiry Price
Size
QTY
Quiflapon sodium
MK591
TQ0098147030-01-1
Quiflapon sodium (MK591) is a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP).
- 80 €
Size
QTY
Select Batch
Purity:99.21%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | AM103 is an effective and selective inhibitor of FLAP (IC50 = 4.2 nM). |
| Targets&IC50 | FLAP:4.2 nM |
| In vitro | AM103 is against the 5 most common CYP isoforms with IC50s >30 μM for CYP2D6 and >50 μM for CYP3A4, CYP2C9, CYP2C19, and CYP1A2[1]. AM103 shows IC50s of 350, 113, and 117 nM against human, rat, and mouse whole-blood ionophore-stimulated LTB4 production, respectively[2]. |
| In vivo | AM103 has high bioavailability of 64%, low clearance of 2.9 mL/min/kg, low volume of distribution of 0.41 L/kg, and a long i.v. half-life of 5.2 h in dogs. AM103 (10 mg/kg) inhibits the increase in CysLTs and EPO by approximately 60% and reduces the level of IL-5[1]. In a model of chronic lung inflammation using ovalbumin-primed and challenged BALB/c mice, AM103 reduces eosinophil peroxidase, CysLTs, and IL-5 in the bronchoalveolar lavage fluid. AM103 increases survival time in mice exposed to a lethal intravenous injection of platelet-activating factor. In the rat lung challenged in vivo with calcium ionophore, AM103 inhibits LTB4 and cysteinyl leukotriene production with ED50 values of 0.8 and 1 mg/kg, respectively[2]. |
| Alias | AM 103 |
| Molecular Weight | 631.76 |
| Formula | C36H38N3NaO4S |
| Cas No. | 1147872-22-7 |
| Smiles | [Na+].COc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C([O-])=O)c(SC(C)(C)C)c3cc(OCc4ccccn4)ccc23)cc1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 180 mg/mL (284 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy AM103 | purchase AM103 | AM103 cost | order AM103 | AM103 chemical structure | AM103 in vivo | AM103 in vitro | AM103 formula | AM103 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.